KYTX vs. HUMA, PROK, CABA, EXAI, VALN, ALEC, ALLO, ADPT, EDIT, and VYGR
Should you be buying Kyverna Therapeutics stock or one of its competitors? The main competitors of Kyverna Therapeutics include Humacyte (HUMA), ProKidney (PROK), Cabaletta Bio (CABA), Exscientia (EXAI), Valneva (VALN), Alector (ALEC), Allogene Therapeutics (ALLO), Adaptive Biotechnologies (ADPT), Editas Medicine (EDIT), and Voyager Therapeutics (VYGR). These companies are all part of the "biological products, except diagnostic" industry.
Humacyte (NASDAQ:HUMA) and Kyverna Therapeutics (NASDAQ:KYTX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, valuation, community ranking, profitability, analyst recommendations, risk, dividends and earnings.
Humacyte currently has a consensus price target of $8.00, suggesting a potential upside of 26.38%. Kyverna Therapeutics has a consensus price target of $42.75, suggesting a potential upside of 177.24%. Given Humacyte's stronger consensus rating and higher probable upside, analysts clearly believe Kyverna Therapeutics is more favorable than Humacyte.
Humacyte's return on equity of 0.00% beat Kyverna Therapeutics' return on equity.
Kyverna Therapeutics has higher revenue and earnings than Humacyte.
In the previous week, Humacyte had 4 more articles in the media than Kyverna Therapeutics. MarketBeat recorded 18 mentions for Humacyte and 14 mentions for Kyverna Therapeutics. Kyverna Therapeutics' average media sentiment score of 0.31 beat Humacyte's score of -0.05 indicating that Humacyte is being referred to more favorably in the media.
44.7% of Humacyte shares are owned by institutional investors. Comparatively, 18.1% of Kyverna Therapeutics shares are owned by institutional investors. 23.1% of Humacyte shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Humacyte received 11 more outperform votes than Kyverna Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Kyverna Therapeutics an outperform vote while only 50.00% of users gave Humacyte an outperform vote.
Summary
Kyverna Therapeutics beats Humacyte on 8 of the 14 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding KYTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Kyverna Therapeutics Competitors List
Related Companies and Tools
